US › Healthcare

Esperion Therapeutics Inc (ESPR)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$3.180.00%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$80.1M
Revenue YoY
+23.2%
Net profit
$-25.2M
Profit YoY
+37.7%
EPS
$-0.10
EPS estimate
$-0.04
Net margin
-31.5%

EPS came in at -0.10 against a street estimate of -0.04 — a miss of 150.0%.

Key statistics

Market cap
$819.5M
P/E
0.0
Forward P/E
4.6
P/B
98.42
Book value
$-1.20
EPS (TTM)
$0.00
52-week high
$4.18
52-week low
$1.34
50-day MA
$3.15
200-day MA
$3.09
Beta
1.06

Analyst view

Analysts rate Esperion Therapeutics Inc a buy (4 buy, 2 hold, 1 sell out of 7) with an average price target of $3.20.

Shareholding

Insiders
0.91%
Institutions
71.54%

Largest institutional holders

FundStake
BlackRock Inc6.93%
Wasatch Advisors LP6.12%
Vanguard Group Inc5.80%
Two Seas Capital LP4.42%
Orbimed Advisors, LLC4.10%
Vanguard Capital Management, LLC4.05%
Two Sigma Investments LLC3.67%
Marshall Wace Asset Management Ltd2.75%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Esperion Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.